Program
serplulimab
Also written as “HLX10”, “Serplulimab + chemotherapy (carboplatin-etoposide)” and “HLX10+chemo”.
Its studies are mostly in Small Cell Lung Carcinoma · Colorectal Neoplasms · Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 3 companies.
Drug pageSerplulimab: every studyAll 107 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 2512 open or running | phase 3since May 6, 2019 | Nov 19, 2018 | none ahead |
| Guangzhou FineImmune Biotechnologyits history only | 11 open or running | phase 1since Mar 4, 2024 | Mar 4, 2024 | none ahead |
| Henlixits history only | 10 open or running | phase 1since Mar 11, 2018 | Mar 11, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Fosun Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 11 earlier studies, Nov 19, 2018 to Jul 7, 2020.
- Jun 9, 2019Named serplulimabINNProposed as its International Nonproprietary Name in WHO's List 121
- Sep 7, 2020Phase 3 study in Colorectal NeoplasmsNCT04547166 · 568 planned · China, Japan
- Mar 17, 2021Phase 3 study in Uterine Cervical NeoplasmsNCT04806945 · China
- Jul 20, 2021Phase 2 study in Squamous Non-small-cell Lung CancerNCT04976647 · 156 enrolled · China
- Jan 22, 2022Phase 2 study in ESCC or Esophageal Adenosquamous CarcinomaNCT05221658 · 60 planned · China
- Feb 16, 2022Phase 2 study in Stomach NeoplasmsNCT05246982 · 40 enrolled · China
- Apr 25, 2022Phase 3 study in Small Cell Lung CarcinomaNCT05353257 · 511 enrolled · United States, Austria, China and more
- Apr 26, 2022Phase 2 study in Small Cell Lung CarcinomaNCT05354700 · 20 enrolled · China
- May 23, 2022Phase 1 study in Adult Solid TumorNCT05400265 · 9 enrolled · China
- Jun 29, 2022Phase 1 study in Solid Tumor, AdultNCT05442996 · 30 planned
- Jul 6, 2022Phase 1 study in Advanced or Metastatic Solid TumorsNCT05483530 · 20 enrolled · Australia
- Jul 11, 2022Phase 2 study in Extensive Stage Small Cell Lung CancerNCT05468489 · 200 enrolled · United States
- Oct 14, 2022Phase 2 study in Colorectal Cancer MetastaticNCT05584137 · 2 enrolled · China
- Nov 15, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05641493 · 49 planned · China
- Jan 22, 2025Phase 2 study in SCLC, Extensive StageNCT06812260 · 26 enrolled · Japan
TargetBeta
“A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 25 Fosun Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06812260SCLC, Extensive Stage · Japan | 2 | Active, not recruiting | Oct 22, 2026 | 26 |
| NCT05641493Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Mar 4, 2025 | 49 |
| NCT05584137Colorectal Cancer Metastatic · China | 2 | Terminated | Dec 31, 2023 | 2 |
| NCT05468489Extensive Stage Small Cell Lung Cancer · United States | 2 | Active, not recruiting | Feb 28, 2026 | 200 |
| NCT05483530Advanced or Metastatic Solid Tumors · Australia | 1 | Active, not recruiting | Dec 2024 | 20 |
| NCT05442996Solid Tumor, Adult | 1 | Not yet recruiting | Apr 22, 2024 | 30 |
| NCT05400265Adult Solid Tumor · China | 1 | Completed | Aug 31, 2023 | 9 |
| NCT05354700Small Cell Lung Carcinoma · China | 2 | UNKNOWN | Mar 29, 2024 | 20 |
| NCT05353257Small Cell Lung Carcinoma · United States, Austria, China and more | 3 | Active, not recruiting | Jun 30, 2026 | 511 |
| NCT05246982Stomach Neoplasms · China | 2 | UNKNOWN | Dec 20, 2023 | 40 |
| NCT05221658ESCC or Esophageal Adenosquamous Carcinoma · China | 2 | Recruiting | Jun 30, 2024 | 60 |
| NCT04976647Squamous Non-small-cell Lung Cancer · China | 2 | UNKNOWN | Jan 30, 2023 | 156 |
| NCT04806945Uterine Cervical Neoplasms · China | 3 | Withdrawn | Feb 15, 2024 | 0 |
| NCT04547166Colorectal Neoplasms · China, Japan | 3 | Recruiting | Sep 24, 2025 | 568 |
| NCT04465734Carcinoma, Hepatocellular · China | 3 | Withdrawn | Oct 15, 2023 | 0 |
| NCT04301739Triple Negative Breast Neoplasms | 3 | Not yet recruiting | Sep 7, 2022 | 522 |
| NCT04150575Uterine Cervical Neoplasms · China | 2 | UNKNOWN | Jun 15, 2022 | 21 |
| NCT04139135Stomach Neoplasms · China | 3 | UNKNOWN | Oct 2023 | 642 |
| NCT04063163Small Cell Lung Carcinoma · Georgia, Poland, Russia and more | 3 | Completed | May 7, 2024 | 585 |
| NCT04033354Neoplasm Metastasis · United States, China, Georgia and more | 3 | Active, not recruiting | Dec 30, 2023 | 537 |
| NCT03973112Carcinoma, Hepatocellular · China | 2 | UNKNOWN | Jun 15, 2022 | 123 |
| NCT03958890Esophageal Squamous Cell Carcinoma · China | 3 | UNKNOWN | Apr 30, 2023 | 489 |
| NCT03952403Carcinoma · China | 3 | Active, not recruiting | Oct 1, 2023 | 643 |
| NCT03941574MSI-H Solid Malignant Tumor · China | 2 | Recruiting | May 30, 2024 | 108 |
| NCT03757936Solid Tumor · China | 1 | UNKNOWN | Sep 27, 2019 | 30 |
How it is read
Names in the registry
- “HLX10”, 15 entries
- “Serplulimab + chemotherapy (carboplatin-etoposide)”, 1 entry
- “HLX10+chemo”, 1 entry
- “Serplulimab Injection”, 1 entry
- “HLX60 combined with HLX10”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
- Colorectal Neoplasms, 2 studies
- Neoplasm Metastasis, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Stomach Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.